Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
- 1 January 2000
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 36 (1), 61-67
- https://doi.org/10.1016/s0959-8049(99)00240-3
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma groupBritish Journal of Cancer, 1998
- Prognostic factors in soft tissue sarcomas: The Aarhus experienceEuropean Journal Of Cancer, 1998
- The role of adjuvant chemotherapy in the treatment of adult soft tissue sarcomasCritical Reviews in Oncology/Hematology, 1998
- Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual dataThe Lancet, 1997
- The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of viewCritical Reviews in Oncology/Hematology, 1995
- High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.Journal of Clinical Oncology, 1995
- The management of adult soft tissue sarcomasClinical Oncology, 1994
- Synovial sarcoma. Uniform response of metastases to high dose ifosfamideCancer, 1994
- Doxorubicin in relapsed soft tissue sarcoma: Justification of phase II evaluation of new drugs in this disease: An EORTC soft tissue and bone sarcoma group studyEuropean Journal of Cancer and Clinical Oncology, 1990
- Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomasEuropean Journal of Cancer and Clinical Oncology, 1987